Dear Clients, Colleagues and Collaborators of Cognate and Cobra, In light of the evolving state of managing the COVID pandemic, Cognate and Cobra wanted to reassure our clients, and ultimately their patients, that we are an essential business, and having modified our schedules are working around the […]
Read more →MEMPHIS, Tenn., January 21, 2019 /PRNewswire/ — Cognate BioServices, a leading contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products today announced that it has completed the acquisition of Cobra Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA […]
Read more →Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products EW Healthcare Partners and its co-investors provide the financing for the transaction MEMPHIS, Tenn., Nov. 4, 2019/PRNewswire/ — Cognate BioServices (Cognate), a leading contract […]
Read more →Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry BALTIMORE & MEMPHIS, Tenn.–(BUSINESS WIRE)–Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it […]
Read more →Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina BASKING RIDGE, NJ, AND MEMPHIS, TENN. (August 7, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company […]
Read more →Memphis, June 10, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced that It has received a statement of compliance for the manufacture and development of advanced therapy medicinal products (ATMPs) for EU/UK. “We’re […]
Read more →Memphis, TN & Menlo Park, CA. January 22nd, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced a letter of intent for a collaboration with Astero Bio Corporation, a leader in the development of innovative […]
Read more →Memphis, TN September 28th, 2018 – Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced a letter of intent for a collaboration agreement with Terumo BCT, a leading technology provider in the cell therapy market. Under the terms […]
Read more →Cognate BioServices and FloDesign Sonics Announce Collaboration to Advance Acoustic Cell Processing as a Platform for Cell Therapy Manufacturing Wilbraham, MA, September 4, 2018 – FloDesign Sonics, a global leader in acoustic cell processing for cell and gene therapies, and Cognate BioServices, a leading contract development and […]
Read more →